Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
Crispr Therapeutics
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Developer of gene-based medicines for serious diseases using its proprietary gene-editing platform

Founded in 2013
Founded in

Company type Public Public (CRSP)
Company type

Industry Group

Sector

TRL Range 9
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Cambridge, MA Cambridge, United States
Address
City
State
Zip
Country

Parent Companies

Website

Traction
  • 0 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
Partnerships
Save
Add Partnership
Date Partner Type
Investment Rounds
Save

IPO INFORMATION

Date

10/18/2016

IPO status

Listed

IPO Type

IPO

Amount

$56M

Initial shares

4000000

Ticker symbol

CRSP

Exchange listed

NASDAQ

Prospectus URL

Prospectus

Source URL

Source

Description

CRISPR Therapeutics AG, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced the pricing of its initial public offering of 4,000,000 common shares at a public offering price of $14.00 per share.

Cancel Save
Add Investment
Date Investors Type Amount
11/08/2016 (0)
Post-money valuation of
This funding, closely following the company's IPO, was disclosed via regulatory filing. There was one undisclosed investor, and the funding was, curiously, attributed to the Swiss subsidiary.
 PIPE $35,000,000
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font